Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 9, 2014, Pages 746-755

  Samara, Sima A ^a   Irshaid, Yacoub M ^a   Mustafa, Khader N ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Jordanians; MDR1; Methotrexate; RFC1; Rheumatoid arthritis

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARABS; ARTHRITIS, RHEUMATOID; FEMALE; GENE FREQUENCY; HUMANS; JORDAN; MALE; METHOTREXATE; MIDDLE AGED; P-GLYCOPROTEIN; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; REDUCED FOLATE CARRIER PROTEIN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905859147     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202098     Document Type: Article

References (55)

1. Gelber AC, Levine SM, Rosen A. Inflammatory Rheumatic Diseases. In: McPhee SJ, Hammer GD (eds). Pathophysiology of Disease. 6th ed. NewYork-McGraw-Hill; 2010.
2. Albers JM, Paimela L, Kurki P, Eberhardt KB, Emery P, van 't Hof MA, Schreuder FH, Leirisalo-Repo M, van Riel PL. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis. 2001; 60: 453-458. CrossRef PubMed (Pubitemid 32417416)
3. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985; 312: 818-822. CrossRef PubMed (Pubitemid 15104774)
4. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, Wolfe F. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford). 2002; 41: 1346-1356. CrossRef PubMed (Pubitemid 36004310)
5. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford). 2002; 41: 1367-1374. CrossRef PubMed (Pubitemid 36004312)
6. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2000; 39: 975-981. CrossRef PubMed
7. Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. 2013; 13: 227-234. CrossRef PubMed
8. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996; 42: 1322-1329. PubMed (Pubitemid 26265051)
9. Swierkot J, Szechiński J. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006; 58: 473-492. PubMed (Pubitemid 44383273)
10. Malaviya AN, Sharma A, Agarwal D, Kapoor S, Garg S, Sawhney S. Low-dose and high-dose methotrexate are two different drugs in practical terms. Int J Rheum Dis. 2010; 13: 288-293. CrossRef PubMed
11. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2008; 47: 249-255. CrossRef PubMed (Pubitemid 351267187)
12. Hinks A, Moncrieffe H, Martin P, Ursu S, Lal S, Kassoumeri L, Weiler T, Glass DN, Thompson SD, Wedderburn LR, Thomson W. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis. 2011; 70: 1395-1400. CrossRef PubMed
13. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4- carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J. 1986; 236: 193-200. PubMed (Pubitemid 16095531)
14. Chabner BA, Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, Ryan D. Cytotoxic Agents. In: L.L. Brunton, B.A. Chabner, B.C. Knollmann (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2011.
15. Smoleńska Z, Kaznowska Z, Zarówny D, Simmonds HA, Smoleński RT. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford). 1999; 38: 997-1002. CrossRef PubMed (Pubitemid 29505083)
16. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005; 57: 163-172. CrossRef PubMed (Pubitemid 41043882)
17. Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford). 2002; 41: 741-749. CrossRef PubMed (Pubitemid 34822955)
18. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009; 68: 1100-1104. CrossRef PubMed
19. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martín-Mola EM, Mielants H, Müller-Ladner U, Murphy G, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009; 68: 1086-1093. CrossRef PubMed
20. Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol. 2008; 64: 1057-1068. CrossRef PubMed
21. Whetstine JR, Gifford AJ, Witt T, Liu XY, Flatley RM, Norris M, Haber M, Taub JW, Ravindranath Y, Matherly LH. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res. 2001; 7: 3416-3422. PubMed (Pubitemid 33069975)
22. Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfister M, Rosenblatt DS, Nicolas JP. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000; 70: 310-315. CrossRef PubMed
23. Chen J, Chen L, Mao N, Liu Y. Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population. Rheumatol Int. 2012; 32: 3127-3130. CrossRef PubMed
24. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001; 11: 217-221. CrossRef PubMed (Pubitemid 32319871)
25. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009; 1794: 860-871. CrossRef PubMed
26. Ishikawa T, Sakurai A, Hirano H, Lezhava A, Sakurai M, Hayashizaki Y. Emerging new technologies in Pharmacogenomics: rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC Transporter ABCB1 (P-gp/MDR1). Pharmacol Ther. 2010; 126: 69-81. CrossRef PubMed
27. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit. 2004; 26: 180-185. CrossRef PubMed (Pubitemid 38501215)
28. Saito K, Miyake S, Moriya H, Yamazaki M, Itoh F, Imai K, Kurosawa N, Owada E, Miyamoto A. Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. Clin Biochem. 2003; 36: 511-518. CrossRef PubMed (Pubitemid 37244012)
29. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legendre C, Thervet E. Association of the multi-drug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003; 14: 1889-1896. CrossRef PubMed (Pubitemid 36750485)
30. Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RH, Molokhia M, Hofman A, Uitterlinden AG, Stricker BH. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008; 18: 299-305. CrossRef PubMed (Pubitemid 351367523)
31. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001; 70: 189-199. CrossRef PubMed (Pubitemid 32777772)
32. Wang H, Ding K, Zhang Y, Jin L, Kullo IJ, He F. Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. Pharmacogenet Genomics. 2007; 17: 667-678. CrossRef PubMed (Pubitemid 47057716)
33. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315-324. CrossRef PubMed (Pubitemid 18091653)
34. van Riel PL, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis. 2000; 59 (Suppl 1): i28-i31. CrossRef PubMed
35. Pincus T, Yazici Y, Bergman M. A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. Best Pract Res Clin Rheumatol. 2007; 21: 755-787. CrossRef PubMed (Pubitemid 47163602)
36. Wang L, Chen W, Wang J, Tan Y, Zhou Y, Ding W, Hua Z, Shen J, Xu Y, Shen H. Reduced folate carrier gene G80A polymorphism is associated with an increased risk of gastroesophageal cancers in a Chinese population. Eur J Cancer. 2006; 42: 3206-3211. CrossRef PubMed (Pubitemid 44854505)
37. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001; 297: 1137-1143. PubMed (Pubitemid 32472514)
38. Hayashi H, Fujimaki C, Daimon T, Tsuboi S, Matsuyama T, Itoh K. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther. 2009; 34: 355-361. CrossRef PubMed
39. Rady PL, Szucs S, Matalon RK, Grady J, Hudnall SD, Kellner LH, Nitowsky H. Genetic polymorphism (G80A) of reduced folate carrier gene in ethnic populations. Mol Genet Metab. 2001; 73: 285-286. CrossRef PubMed (Pubitemid 32709620)
40. Ghodke Y, Chopra A, Shintre P, Puranik A, Joshi K, Patwardhan B. Profiling single nucleotide polymorphisms (SNPs) across intracellular folate metabolic pathway in healthy Indians. Indian J Med Res. 2011; 133: 274-279. PubMed
41. Takatori R, Takahashi KA, Tokunaga D, Hojo T, Fujioka M, Asano T, Hirata T, Kawahito Y, Satomi Y, Nishino H, Tanaka T, Hirota Y, Kubo T. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol. 2006; 24: 546-554. PubMed (Pubitemid 44911249)
42. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006; 54: 3095-3103. CrossRef PubMed (Pubitemid 44622078)
43. Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006; 54: 1087-1095. CrossRef PubMed (Pubitemid 43672921)
44. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004; 50: 2766-2774. CrossRef PubMed (Pubitemid 39209513)
45. Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G, Smith K, Caldwell J, Furst DE. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics. 2004; 14: 733-739. CrossRef PubMed (Pubitemid 39552788)
46. Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J. 2007; 7: 404-407. CrossRef PubMed (Pubitemid 350192886)
47. Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, Carlsen N, Schmiegelow K, Peterson C. The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood. 2010; 115: 4671-4677. CrossRef PubMed
48. Laverdière C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood. 2002; 100: 3832-3834. CrossRef PubMed (Pubitemid 35303961)
49. Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007; 109: 4151-4157. CrossRef PubMed (Pubitemid 46743376)
50. Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JN, Smith CH. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol. 2007; 127: 1860-1867. CrossRef PubMed (Pubitemid 47075365)
51. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M, Okumura K. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007; 52: 166-171. CrossRef PubMed (Pubitemid 46188292)
52. Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2004; 42: 496-503. CrossRef PubMed (Pubitemid 39255621)
53. Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herczynska M. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol. 2006; 62: 933-937. CrossRef PubMed (Pubitemid 44657627)
54. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000; 97: 3473-3478. CrossRef PubMed (Pubitemid 30183327)
55. van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001; 44: 1515-1524. CrossRef PubMed (Pubitemid 32651731)